Document Detail


Safety and feasibility of collateral blood flow augmentation after intravenous thrombolysis.
MedLine Citation:
PMID:  21350210     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND PURPOSE: Collateral flow augmentation using partial aortic occlusion may improve cerebral perfusion in acute stroke. We assessed the safety and feasibility of partial aortic occlusion immediately after intravenous tissue plasminogen activator.
METHODS: We conducted an open-label pilot study of partial aortic occlusion after thrombolysis. The primary end point was all serious adverse events within 30 days of treatment.
RESULTS: None of the 22 patients enrolled developed symptomatic parenchymal hemorrhages. Asymptomatic hemorrhagic transformation occurred in 9 patients. Procedure-related adverse events were limited to groin complications (n=13). Seventy-seven percent of patients experienced neurological improvement (≥4-point improvement of the National Institutes of Health Stroke Scale score).
CONCLUSIONS: Partial aortic occlusion as an adjunct to thrombolysis in the treatment of acute stroke appears safe. Studies aimed at determining the efficacy of this therapeutic approach are warranted.
CLINICAL TRIAL REGISTRATION INFORMATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01006993.
Authors:
Derek J Emery; Peter D Schellinger; Daniel Selchen; Andre G Douen; Richard Chan; Ashfaq Shuaib; Kenneth S Butcher
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2011-02-24
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  42     ISSN:  1524-4628     ISO Abbreviation:  Stroke     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-03-29     Completed Date:  2011-05-31     Revised Date:  2012-09-10    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1135-7     Citation Subset:  IM    
Affiliation:
Department of Radiology, University of Alberta, Edmonton, Alberta, Canada.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT01006993
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Aorta, Abdominal / physiopathology
Balloon Occlusion / adverse effects,  instrumentation,  methods*
Cerebrovascular Circulation / drug effects,  physiology*
Combined Modality Therapy / instrumentation,  methods*
Female
Fibrinolytic Agents / administration & dosage
Humans
Hypoxia-Ischemia, Brain / physiopathology,  therapy*
Infusions, Intravenous / methods
Male
Middle Aged
Pilot Projects
Thrombolytic Therapy / methods*
Tissue Plasminogen Activator / administration & dosage
Grant Support
ID/Acronym/Agency:
//Canadian Institutes of Health Research
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increased Thyroid Function and Elevated Thyroid Autoantibodies in Pediatric Patients With Moyamoya D...
Next Document:  Disturbed blood flow induces RelA expression via c-Jun N-terminal kinase 1: a novel mode of NF-?B re...